Johnson & Johnson (JNJ) Cash & Equivalents (2009 - 2026)

Johnson & Johnson has reported Cash & Equivalents for 18 years, with the latest figure at $20.4 billion in Q2 2026.

• Quarterly Cash & Equivalents rose 9.93% year-over-year to $20.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.4 billion (up 9.93% YoY) and the FY2025 annual result came in at $19.7 billion, down 18.24% from the prior year.
• Cash & Equivalents retreated to $20.4 billion in Q2 2026 per JNJ's latest filing, from $21.7 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $38.5 billion in Q1 2025 and troughed at $10.5 billion in Q2 2022.
• A 5-year average of $19.7 billion and a median of $19.7 billion in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents soared 92.87% in 2023, then slumped 43.63% in 2026.
• Over 5 years, Cash & Equivalents stood at $11.4 billion in 2022, then surged by 92.51% to $21.9 billion in 2023, then gained by 10.27% to $24.1 billion in 2024, then decreased by 18.24% to $19.7 billion in 2025, then climbed by 3.62% to $20.4 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $20.4 billion, $21.7 billion, and $19.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.